Zobrazeno 1 - 5
of 5
pro vyhledávání: '"D. Yu. Yukalchuk"'
Autor:
N. S. Besova, T. A. Titova, Е. V. Artamonova, A. A. Tryakin, D. L. Stroyakovskiy, E. V. Perminova, D. Yu. Yukalchuk, D. M. Ponomarenko, N. P. Belyak, R. V. Orlova, G. M. Teletaeva, E. Yu. Ratner, A. S. Mochalova, O. O. Gordeeva, A. S. Zhabina, S. V. Gamayunov, A. V. Smolin, A. Yu. Povyshev, M. I. Andrievskikh, I. S. Stilidi
Publikováno v:
Медицинский совет, Vol 0, Iss 9, Pp 165-174 (2020)
Background. Ramucirumab is a monoclonal antibody that inhibits the vascular endothelial growth factor receptor-2 (VEGFR2). The study is aimed to analyse prognostic factors for survival in patients with disseminated gastric cancer who received ramucir
Externí odkaz:
https://doaj.org/article/c36b27f6439d4e80b0427ab6e064acee
Autor:
I. A. Pokataev, M. A. Lyadova, M. Yu. Fedyanin, A. A. Tryakin, V. F. Chubenko, F. V. Moiseenko, L. A. Zagorskaya, M. L. Stepanova, A. V. Androsova, D. A. Nosov, N. V. Karpova, O. I. Kit, L. Yu. Vladimirova, I. L. Popova, A. V. Belonogov, D. M. Ponomarenko, D. Yu. Yukalchuk, V. E. Shikina, N. V. Ivanova, A. I. Khasanova, A. D. Kruglov, I. Yu. Stradaeva, A. S. Perepletova, V. M. Filippova, N. L. Buzova, O. V. Khavaneva, Kh. S. Musaeva, A. Yu. Goryainova, O. V. Romanchuk, I. Sh. Tespizhek, S. A. Tyulyandin
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 74-82 (2019)
Introduction. The randomized MPACT study showed that nab-paclitaxel plus gemcitabine results in statistically significantly longer life expectancy. The objective of this retrospective study is to obtain relevant data on the efficacy of this combinati
Externí odkaz:
https://doaj.org/article/edea90a163bc42438bb0f9e0ef411a7b
Autor:
D. I. Yudin, K. K. Laktionov, F. V. Moiseenko, D. M. Ponomarenko, E. A. Chekh, V. A. Chubenko, N. V. Levchenko, V. V. Kozlov, E. О. Stepanova, K. A. Sarantseva, E. S. Denisova, M. S. Ardzinba, D. Yu. Yukalchuk
Publikováno v:
Meditsinskiy sovet = Medical Council. :12-20
Introduction. The addition of durvalumab after chemoradiation therapy in unresectable stage III non-small-cell lung cancer (NSLC) is a new standard of care.Aim. Study the features and outcomes of durvalumab maintenance treatment after chemoradiothera
Publikováno v:
Medical alphabet. 3:5-8
Non-small cell lung cancer (NSCLC) continues be one of the most frequent oncological diseases both in incidence and mortality. Over the past ten years, due to the targeted and immunotherapy, significant success has been achieved in the treatment of m
Autor:
R V Orlova, L G Zhukova, I P Ganshina, D Yu Yukalchuk, D M Ponomarenko, N P Beliak, O O Gordeeva, S P Erdniev, A A Minasyan, A A Dashkova, E R Sopiya, E A Sholokhova, A B Gurochkin
Publikováno v:
Современная онкология, Vol 20, Iss 1, Pp 35-41 (2018)
Background. Gastric cancer is the fifth most common malignancy worldwide with diagnosis often occurring at an advanced stage. For the majority of advanced gastric cancer patients, chemotherapy typically is used as first-line treatment, although many